NEW Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the diabetes medicine Vildagliptin and Vildagliptin /Metformin in Africa
We at Tiefenbacher Pharmaceuticals strive to make our high-quality medicines available and affordable to as many people as possible around the world. Therefore Tiefenbacher Group is happy to share that we have successfully prepared the launch of the generic version of Vildagliptin and the combination product Vildagliptin/Metformin in Africa.
Generally, Vildagliptin and Vildagliptin/Metformin are diabetes medicines that are used to control the blood glucose (sugar) in adults with type 2 diabetes. The tablets are marketed in South Africa (Vildagliptin 50 mg) and Namibia (Vildagliptin/Metformin 50/1000 mg) by our marketing partner, a well-known South African based pharmaceutical company.
We develop the products in our own laboratories in Hyderabad, India. Afterwards they will be marketed in Europe and further international countries as soon as the patents of the originator products have expired.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
